6thJune, 2024
09:00 - 09:30OMEGA I


Parliamentary Secretary at Ministry of Health of Latvia Artjoms Uršuļskis

President of World Psychiatric Association Prof. Danuta Wasserman

Ex-President of the Republic of Latvia Prof. Dr. Vaira Vīķe-Freiberga


09:30 - 10:30OMEGA I

Plenary. Prof. Norman Sartorius "The Future of Medicine and Psychiatry"

Abstract: The future of medicine and psychiatry will be shaped by powerful social and economic trends – such as urbanization and horizontalization of human relationships – and it is of essential importance to adjust the training in medicine and psychiatry as well as the organization of mental health services to the changes of society and of medicine which these trends will produce. The presentation will describe these trends and their impact and make suggestions about the way in which medicine and psychiatry should respond in order to remain useful and effective.


10:30 - 11:00

Coffee Break

11:00 - 12:30OMEGA I

Symposium Norway: What should a psychiatrists do; how do we shape our role in the treatment team? Experiences from Norway, Sweden and Finland. Chairs: Prof. Lars Lien (Norway) and Prof. Solveig Klæbo Reitan (Norway)


Shahram Shaygani (Norway). "What should a psychiatrists do; how do we shapeour role in the treatment team?"

Maria Larsson (Sweden). "The future role of a psychiatrist and how we shape the role together"

Erfan Jahangiri (Finland). "Entering psychiatry as an early career psychiatrist - viewpoint of a medical director" 

11:00 - 12:30OMEGA II

Symposium Lithuania: What is behind “I'm so tired”? Defining and measuring fatigue. Chairs: Ramune Mazaliauskiene (Lithuania) and Marija Abeltina (Latvia)


Agne Stanyte (PhD student- early career), Lithuania.  "Mental Fatigue in Individuals with Psychiatric Disorders"

Prof. Vesta Steibliene, Lithuania. "Fatigue and the Role of Personality"

Julius Burkauskas (PhD. - mid career) Lithuania-UK. "Fatigue, Social Support, and Depression in Individuals with Coronary Artery Disease"

Marija Abeltina (PhD. - mid career), Latvia. "Mental Health and Work Engagement as Predictors of Different Burnout Conceptualizations"

11:00 - 12:30ALFA

Symposium Finland: Neuromodulation therapies. Chairs: Assistant Prof. Erika Jääskeläinen (Finland) and Prof. Elmars Rancans (Latvia)


11.00-11.10 Erika Jääskeläinen (Finland). "Welcome and introduction - Effectiveness on neuromodulation treatments" 

11.10-11.30 MD Matias Leppäaho (Finland) "Increase in the use of electroconvulsive therapy between 2012-2022 in the Northern Finland"

11.30-12.00 MD, CMO, President Emeritus of SPA Martin Hulten (Sweden). "Results from The Swedish National Quality Registry for ECT" 

12.00-12.20 MD Saana Karttunen, (Finland). "Use and experience of rTMS in acute and maintenance treatment in Finland"

12.20-12.30 discussion and closing of the symposium

11:00 - 12:30BETA I+II

Bronze Sponsor (Boehringer Ingelheim) Symposium: Cognitive impairment in Schizophrenia. Chair: prof. Māris Taube (President of Latvian Psychiatric association) 

Draft agenda 

11:00-11:10 Opening and introduction

11:10-11:35 Understanding the relationship between cognition and functioning in schizophrenia and its impact to daily living (Assoc. prof. Lubova Renemane, Latvia)

11:35-12:00 Evaluation and monitoring of cognition in patients with schizophrenia in clinical practice (Camilla Barthel Flaaten, Norway)

12:00-12:15 Future of management of cognitive impairement in schizophrenia (Liene Sīle, Latvia)

12:15-12:30 Discussion and closing.

12:30 - 13:30

Lunch/Poster Presentations

13:30 - 14:30OMEGA I

Plenary. Prof. Katharina Domschke “Update on Anxiety Disorders – Epidemiology, Taxonomy, Etiology and Treatment”

Abstract: With a 12-month prevalence of 14% and around 61.5 million people affected in the European Union, anxiety disorders are among the most common mental illnesses and are associated with a high socio-economic burden. This plenary lecture will present the latest data on epidemiology, taxonomy, etiology as well as psychotherapeutic and pharmacotherapeutic approaches to anxiety disorders.

14:40 - 16:00OMEGA I

Joint Symposium: What it takes to become a psychiatrist? Continues medical education of psychiatrists – experiences from Norway, Latvia and Lithuania. Chairs: Prof. Elmars Rancans (Latvia) and Niclas Halvorsen (Norway)


Dr. Liene Vitola, CAP, Chair of Young Psychiatrist section of Latvian Psychiatric Association (Latvia). "Becoming a child and adolescents psychiatrist in Latvia: pros and cons of existing system"

Dr. Ulrika Larsson (Norway). "The role of NCP in securing high standard psychiatrists in Norway"

Dr. Ramune Mazaliauskiene, President of the Nordic Psychiatric association (Lithuania). "The education of young psychiatrists in Lithuania"

14:40 - 16:00OMEGA II

Symposium Iceland: Increase in prescribing of ADHD medication in Iceland: risk of psychotic episodes, abuse and antipsychotic prescribing. Chair: Associate Professor Halldóra Jónsdóttir (Iceland)


Assistant Prof. Oddur Ingimarsson (Iceland). "ADHD medication and psychotic episodes, prevalence in Iceland". 

Prof. Engibert Sigurðsson (Iceland). "Why is antipsychotic prescribing common for individuals on ADHD medication?"

Assistant Prof. Guðrún Dóra Bjarnadóttir (Iceland). "Methylphenidate is the drug of choice among iv substance abusers in Iceland" 


14:40 - 16:00BETA I+II

Symposium Estonia: Different Approaches for schizophrenia treatment. Chairs: Associate Professor Liina Harig (Estonia) and Liene Sile (Latvia)


Marika Garnizone (Latvia). "Early intervention team for first time psychosis patients - Latvian experience"

Liina Haring (Estonia). „Research on schizophrenia spectrum disorders in Estonia: Yesterday, Today and Tomorrow“

Liisa Leppik (Estonia). "Biomarkers in the early course of psychotic disorders”

Karola Peebo (Estonia). „First-episode psychosis integrative treatment: Estonian experience“



14:40 - 16:00ALFA

Nordic Symposium. Highlights from Nordic Journal of Psychiatry. Chairs: Martin Balslev Jorgensen (Denmark) and Hans-Peter Mofos (Sweden)

1. Martin Balslev Jørgensen, Denmark. "Trends and publications in the Nordic Journal of Psychiatry“ 

2. Jelena Vrublevska, Latvia. "Depression, distress, and selfreported changes in anxiety, depression, and suicidal thoughts during the COVID-19 state of emergency in Latvia" 

3. Merete Nordentoft, Denmark. "Incidence rates and employment trends in schizophrenia spectrum disorders, bipolar affective disorders and recurrent depression in Denmark" 

4. Martin Balslev Jørgensen, Denmark. "Treatment of difficult-to-treat depression - clinical guideline for selected interventions"

16:30 - 17:30OMEGA I

Gold Sponsor (Gedeon Richter) Symposium: Dual Disorders and their Impact on Recovery in Patients with Schizophrenia. Chair: Prof. Elmars Rancans (Latvia)


Prof. Elmars Rancans. "Concomitant drug abuse as a hurdle in schizophrenia recovery"

Prof. Stephen Hjorth. "Dopamine D3 receptors in the treatment of dual schizophrenia & SUD"

Assoc. prof. Jelena Vrublevska. "Evidence-based patient treatment – the way from polypharmacy to monotherapy in dual schizophrenia"

Abstract: Comorbid substance use disorder is a major hurdle in the schizophrenia recovery process. To successfully treat dual schizophrenia an integrated and personalized approach needs to be considered. The symposium aims to present the problem of dual schizophrenia and its impact on the recovery of patients. It addresses the benefits of partial agonist drugs in the treatment of the disorder and discusses aspects of antipsychotic polypharmacy, offering a pharmacological rationale and guidance for the use of APs in a real-world setting. Finally, a case presentation where polypharmacy was successfully applied in a dual disorder patient in clinical practice will round up the symposium.



Social event + dinner included "Mazā ģilde" Amatu street 5, Riga